يعرض 1 - 10 نتائج من 216 نتيجة بحث عن '"Philipp Le Coutre"', وقت الاستعلام: 0.75s تنقيح النتائج
  1. 1
    دورية أكاديمية
    VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge

    المؤلفون: Virginie Kreutzinger, Anne Pankow, Zhivana Boyadzhieva, Udo Schneider, Katharina Ziegeler, Lars Uwe Stephan, Jan Carl Kübke, Sebastian Schröder, Christian Oberender, Philipp le Coutre, Sebastian Stintzing, Ivan Jelas

    المصدر: Journal of Clinical Medicine, Vol 13, Iss 4, p 1049 (2024)

    مصطلحات موضوعية: autoinflammation, imaging, myelodysplastic syndrome, VEXAS syndrome, Medicine

    وصف الملف: electronic resource

    العلاقة: https://www.mdpi.com/2077-0383/13/4/1049Test; https://doaj.org/toc/2077-0383Test

    الوصول الحر: https://doaj.org/article/9facf3ef4dea4d0885b4bef8d0e029aaTest

    View record in DOAJ النص الكامل

    أضف إلى المفضلة
  2. 2
    A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

    المؤلفون: Philipp le Coutre, Véronique Bédoucha, Delphine Rea, Dennis Dong Hwan Kim, Elza Lomaia, Michael J. Mauro, Andre Abdo, Lynette Chee, Sergey Voloshin, Dong-Wook Kim, Laura Fogliatto, Paola Aimone, Yosuke Minami, Alex Allepuz, Mario Annunziata, Jane F. Apperley, Susanne Saussele, Jorge E. Cortes, Andreas Hochhaus, Naeem Chaudhri, Carla Boquimpani, Koji Sasaki, Sara Quenet, Timothy P. Hughes, Anna G. Turkina, Valentín García-Gutiérrez

    المصدر: Blood

    مصطلحات موضوعية: Adult, Male, Niacinamide, Oncology, medicine.medical_specialty, Randomization, Clinical Trials and Observations, Immunology, Antineoplastic Agents, Biochemistry, law.invention, Young Adult, Randomized controlled trial, law, Internal medicine, Nitriles, medicine, Humans, Adverse effect, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Aniline Compounds, business.industry, Myeloid leukemia, Cell Biology, Hematology, Middle Aged, Discontinuation, Treatment Outcome, Leukemia, Myeloid, Chronic-Phase, Quinolines, Pyrazoles, Female, Open label, business, Bosutinib, Tyrosine kinase, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68ea953c680d4e6fe9a23516537c5aa9Test
    https://doi.org/10.1182/blood.2020009984Test


    أضف إلى المفضلة
  3. 3
    Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

    المؤلفون: Michael Heinrich, Michael W. Deininger, Andreas Hochhaus, Laura Stenson, Paola Aimone, Fotis Polydoros, Dong-Wook Kim, Gabriel Etienne, Timothy P. Hughes, Massimo Breccia, Philipp le Coutre, Jorge E. Cortes, Fabian Lang, Moshe Talpaz, Juan Luis Steegmann, Jeroen Janssen, Silvia Cacciatore, Michael J. Mauro, Yeow Tee Goh, Delphine Rea

    المصدر: Blood. 136:47-50

    مصطلحات موضوعية: business.industry, Molecular Response, Immunology, Cancer research, Medicine, Myeloid leukemia, In patient, Cell Biology, Hematology, business, Biochemistry, T315i mutation

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::8bcb52be13db6a5f9369b332be0df5cbTest
    https://doi.org/10.1182/blood-2020-139677Test


    أضف إلى المفضلة
  4. 4
    Single-cell analysis based dissection of clonality in myelofibrosis

    المؤلفون: Christopher C. Oakes, Elena Mylonas, Yusuke Shiozawa, Lars Bullinger, Matthias Obenaus, Daniel Noerenberg, Mareike Frick, Michaela Schwarz, Matthew J. J. Rose-Zerilli, Kenichi Yoshida, Friederike Christen, Yotaro Ochi, Willy Chan, Frederik Damm, Jaspal Kaeda, Philipp le Coutre, Yuichi Shiraishi, Seishi Ogawa, Thorsten Zenz, Birgit Sawitzki, Kaja Hoyer, Cornelius Hennch

    المساهمون: University of Zurich, Damm, Frederik

    المصدر: Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
    Nature Communications

    مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Neuroblastoma RAS viral oncogene homolog, Ruxolitinib, Cancer Research, Myeloid, Somatic cell, General Physics and Astronomy, medicine.disease_cause, Somatic evolution in cancer, Biochemistry, Loss of heterozygosity, 0302 clinical medicine, Single-cell analysis, Genotype, Cancer genomics, Medicine, Exome, Prospective Studies, lcsh:Science, Cancer genetics, Genetics, Mutation, Multidisciplinary, Stem Cells, Hematology, Middle Aged, 3100 General Physics and Astronomy, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, KRAS, Single-Cell Analysis, medicine.drug, medicine.medical_specialty, Science, Immunology, 610 Medicine & health, 1600 General Chemistry, Biology, Oncogene Protein p21(ras), General Biochemistry, Genetics and Molecular Biology, Article, Clonal Evolution, Genetic Heterogeneity, 03 medical and health sciences, 1300 General Biochemistry, Genetics and Molecular Biology, Internal medicine, Humans, Myelofibrosis, Allele frequency, Aged, Haematological cancer, Genetic heterogeneity, business.industry, General Chemistry, Cell Biology, medicine.disease, 030104 developmental biology, Tumor progression, Primary Myelofibrosis, 10032 Clinic for Oncology and Hematology, lcsh:Q, business, Follow-Up Studies, 030215 immunology

    وصف الملف: s41467-019-13892-x.pdf - application/pdf; application/pdf; text

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a3708a3b78d2b6ca5768702654f70b0Test
    https://doaj.org/article/7e23582169274e9ab60ff7109190fa37Test


    أضف إلى المفضلة
  5. 5
    Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management

    المؤلفون: Cornelius F. Waller, Wilhelm Haverkamp, Christina Rieger, Frank Stegelmann, Fabian Lang, Kathleen Jentsch-Ullrich, Paul La Rosée, Philipp le Coutre, Susanne Saussele, Georg-Nikolaus Franke, Steffen Koschmieder, Heike Pfeifer, Rudolf Kirchmair, Christian Junghanss, Nicola Goekbuget, Alexander Kiani

    المصدر: Acta Haematol
    Acta haematologica 143(3), 217-231 (2020). doi:10.1159/000501927

    مصطلحات موضوعية: Male, Oncology, Fusion Proteins, bcr-abl, Refractory CML, Review, Tyrosine-kinase inhibitor, chemistry.chemical_compound, 0302 clinical medicine, hemic and lymphatic diseases, Philadelphia Chromosome, Clinical Trials as Topic, Acute leukemia, Philadelphia Chromosome Positive, Ponatinib, Imidazoles, Myeloid leukemia, Hematology, General Medicine, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Progression-Free Survival, Pyridazines, Cardiovascular Diseases, 030220 oncology & carcinogenesis, Hypertension, Female, Tyrosine kinase, Adult, medicine.medical_specialty, medicine.drug_class, Antineoplastic Agents, Hyperlipidemias, Risk Assessment, 03 medical and health sciences, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, ddc:610, Protein Kinase Inhibitors, Aged, Dose-Response Relationship, Drug, business.industry, Expert consensus, respiratory tract diseases, chemistry, Drug Resistance, Neoplasm, Hyperglycemia, business, 030215 immunology

    وصف الملف: application/octet-stream

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::110332b37a313083092a07d535bca7a8Test
    https://doi.org/10.1159/000501927Test


    أضف إلى المفضلة
  6. 6
    Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia:5-year update of the ENESTfreedom trial

    المؤلفون: Jerald P. Radich, David M. Ross, Bruno Martino, Susanne Saussele, María Teresa Gómez Casares, Andreas Hochhaus, Eibhlin Conneally, Giuseppe Saglio, Philipp le Coutre, Norbert Gattermann, Tamás Masszi, Sai Li, Francis J. Giles, Jesper Stentoft, Andrzej Hellmann, Paola Aimone, Ksenia Titorenko, J. Valentín García-Gutiérrez

    المصدر: Radich, J P, Hochhaus, A, Masszi, T, Hellmann, A, Stentoft, J, Casares, M T G, García-Gutiérrez, J V, Conneally, E, le Coutre, P D, Gattermann, N, Martino, B, Saussele, S, Giles, F J, Ross, D M, Aimone, P, Li, S, Titorenko, K & Saglio, G 2021, ' Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia : 5-year update of the ENESTfreedom trial ', Leukemia, vol. 35, no. 5, pp. 1344-1355 . https://doi.org/10.1038/s41375-021-01205-5Test
    Leukemia

    مصطلحات موضوعية: Male, Cancer Research, medicine.medical_specialty, Adolescent, Protein Kinase Inhibitors/therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, DISCONTINUATION, Kaplan-Meier Estimate, IMATINIB, Article, Phase II trials, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, MANAGEMENT, Humans, In patient, Adverse effect, MAJOR MOLECULAR RESPONSE, Protein Kinase Inhibitors, Survival rate, CML, Chronic myeloid leukaemia, DASATINIB, Framingham Risk Score, business.industry, Leukemia, Myeloid, Chronic-Phase/drug therapy, Incidence (epidemiology), KINASE INHIBITOR THERAPY, Myeloid leukemia, Pyrimidines/therapeutic use, Hematology, Chronic phase chronic myeloid leukemia, Survival Rate, Pyrimidines, Treatment Outcome, Oncology, Nilotinib, Leukemia, Myeloid, Chronic-Phase, SURVIVAL, Female, CESSATION, business, medicine.drug

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9b2998b5b263037b3d3f86c7e5684fcTest
    https://pure.au.dk/portal/da/publications/treatmentfree-remission-following-frontline-nilotinib-in-patients-with-chronic-phase-chronic-myeloid-leukemiaTest(8a362493-6e7f-4345-a1da-c05d5478eeb8).html


    أضف إلى المفضلة
  7. 7
    CML-081: Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION

    المؤلفون: Massimo Breccia, Irene DeGutis, Philipp le Coutre, Oumar Sy, Antonio Jiménez-Velasco, Elias Jabbour, Rene Swanink, Giuseppe Saglio, Jorge E. Cortes, Michael J. Mauro, Wasiulla Khan

    المصدر: Clinical Lymphoma Myeloma and Leukemia. 21:S326-S327

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Proportional hazards model, business.industry, medicine.drug_class, Imatinib, Hematology, medicine.disease, Comorbidity, Tyrosine-kinase inhibitor, Discontinuation, Dasatinib, hemic and lymphatic diseases, Internal medicine, Post-hoc analysis, medicine, Adverse effect, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::fb10ce90cd5d7533bbe40155604344d9Test
    https://doi.org/10.1016/s2152-2650Test(21)01766-3


    أضف إلى المفضلة
  8. 8
    Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

    المؤلفون: Ian W. Flinn, Ksenia Titorenko, Carla Boquimpani, Gabriel Etienne, Richard E. Clark, Israel Bendit, Surapol Issaragrisil, Richard A. Larson, Timothy P. Hughes, Dong-Wook Kim, Andreas Hochhaus, Maria Aparecida Zanichelli, Slawomira Kyrcz-Krzemien, Silvia Cacciatore, Giuseppe Saglio, Hagop M. Kantarjian, Ewa Medras, Paola Aimone, Philipp le Coutre, Viviane Dubruille, Ricardo Pasquini

    المصدر: Leukemia. 35:2142-2143

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Myeloid leukemia, Imatinib, Hematology, Newly diagnosed, medicine.disease, Leukemia, Nilotinib, Internal medicine, medicine, Long term outcomes, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ae87a9c2b6125fef080a83a755f1e04dTest
    https://doi.org/10.1038/s41375-021-01306-1Test


    أضف إلى المفضلة
  9. 9
    Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

    المؤلفون: Carla Boquimpani, Gabriel Etienne, Israel Bendit, Philipp le Coutre, Ksenia Titorenko, Timothy P. Hughes, Ewa Medras, Viviane Dubruille, Silvia Cacciatore, Paola Aimone, Hagop M. Kantarjian, Ricardo Pasquini, Giuseppe Saglio, Dong-Wook Kim, Slawomira Kyrcz-Krzemien, Richard E. Clark, Maria Aparecida Zanichelli, Andreas Hochhaus, Surapol Issaragrisil, Richard A. Larson, Ian W. Flinn

    المصدر: Leukemia

    مصطلحات موضوعية: Oncology, Male, Cancer Research, medicine.medical_specialty, Context (language use), Newly diagnosed, Article, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Combined Chemotherapy Protocols, Long term outcomes, medicine, Humans, Adverse effect, neoplasms, Chronic myeloid leukaemia, Haematological cancer, Framingham Risk Score, business.industry, Myeloid leukemia, Correction, Imatinib, Hematology, Middle Aged, Prognosis, Survival Rate, Pyrimidines, Nilotinib, Imatinib Mesylate, Female, business, medicine.drug, Follow-Up Studies

    وصف الملف: application/vnd.openxmlformats-officedocument.wordprocessingml.document

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f51ac7fae4b80e1587ed6dbe67919d6Test
    https://pubmed.ncbi.nlm.nih.gov/34108614Test


    أضف إلى المفضلة
  10. 10
    Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

    المؤلفون: Naeem Chaudhri, Michael J. Mauro, Koji Sasaki, Sergey Voloshin, Dennis Dong Hwan Kim, Valentín García Gutiérrez, Timothy P. Hughes, Carla Boquimpani, Lynette C.Y. Chee, Jorge E. Cortes, Anna G. Turkina, Sarah Quenet, Andre Abdo, Andreas Hochhaus, Shruti Kapoor, Yosuke Minami, Jane F. Apperley, Susanne Saussele, Dong-Wook Kim, Laura Fogliatto, Delphine Rea, Véronique Bédoucha, Mario Annunziata, Elza Lomaia, Philipp le Coutre, Alex Allepuz

    المصدر: Blood. 138:310-310

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Immunology, Myeloid leukemia, Phases of clinical research, Cell Biology, Hematology, Biochemistry, Internal medicine, medicine, In patient, Open label, business, Bosutinib, Tyrosine kinase, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::7dd81eaa120fe3ae5a6bf3d8985e98e2Test
    https://doi.org/10.1182/blood-2021-152561Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث